Batermere, good luck in whatever you decide. Just my two cents worth, I would think twice before selling down here. On the one hand, I very much feel your pain and one could argue considering the company has lost 80% of its value over the last several years, selling now will ensure we won't loose the remaining 20% (should the stock go to $0). That said, look at what transpired since 2013. O'Connor raised $250 million and squandered it via reckless spending, unfocused and misguiding business strategy and show boating and self dealing to pay himself unearned compensation. He basically burned the bridge to investors and lost all confidence Wall Street had in the company. This became apparent when a year ago he was let go because of the unsustainable spend coupled with another deceptive tactic to transfer unearned shareholder assets to himself and not delivering any monetary deal on AXAL. Now we learn that AXAL, which he spent the majority of his time spending money on and holding out on partnering to go it alone for the better of four years, may be scrapped because it is becoming outdated at this point and there is little demand to pay up for it. You can't make this up. Harvard Business School should write a case study on ADXS about how poor management can decimate an investor ROI despite impressive advancement of the clinical program and attractive technology. My point is, unlike O'Connor, Berlin is a real CEO with alignment with our interest and IMO he is honest and will rebuild investor trust. We've finally gotten the management equation right IMO. If the technology is still valid, which the clinical data would say it is, Berlin should be able to rebuild the value O'Connor (and Lombardo) destroyed and get us back up to fair value of $10+ pps ($500m+ market cap).
